Yan-Wen Bi Selected Research

salicylhydroxamic acid (SHAM)

7/2015

Olmesartan restores the protective effect of remote ischemic perconditioning against myocardial ischemia/reperfusion injury in spontaneously hypertensive rats.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yan-Wen Bi Research Topics

Disease

2	Hypoxia (Hypoxemia) 01/2022 - 06/2015
2	Ischemia 07/2015 - 06/2015
2	Reperfusion Injury 07/2015 - 06/2015
1	Pulmonary Arterial Hypertension 01/2022
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2022
1	Right Ventricular Hypertrophy 01/2022
1	Cardiac Arrhythmias (Arrythmia) 07/2015
1	Hypertrophy 07/2015
1	Infarction (Infarctions) 07/2015
1	Myocardial Ischemia (Ischemic Heart Diseases) 07/2015
1	Cardiovascular Diseases (Cardiovascular Disease) 06/2015

Drug/Important Bio-Agent (IBA)

2	olmesartanIBA 07/2015 - 06/2015
2	Messenger RNA (mRNA)IBA 07/2015 - 06/2015
2	Creatine Kinase (Creatine Phosphokinase)IBA 07/2015 - 06/2015
1	AldehydesIBA 01/2022
1	CytokinesIBA 01/2022
1	Alprostadil (Muse)FDA LinkGeneric 01/2022
1	CXC ChemokinesIBA 01/2022
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022
1	Hypoxia-Inducible Factor 1IBA 01/2022
1	salicylhydroxamic acid (SHAM)IBA 07/2015
1	HMGB1 Protein (HMG1)IBA 06/2015
1	Angiotensin Receptor AntagonistsIBA 06/2015